KalVista Pharmaceuticals

Money Moves

Target

For decades, people with hereditary angioedema—a genetic condition where the immune system misfires and swells tissues shut, sometimes fatally—had only one option when an attack hit: injecting themselves, often in a panic, to stop swelling that can close the airway. In July 2025, a pill changed that. On Wednesday, Italian drugmaker Chiesi Farmaceutici agreed to buy the pill's maker, KalVista Pharmaceuticals, for about $1.9 billion in cash—the largest acquisition in Chiesi's 90-year history.

Updated Apr 30